Research

Mixed

Endoscopic Bariatric Procedures (EBP), including intragastric balloon (IGB), aspiration therapy (AT), and primary obesity surgery endoluminal (POSE), are generally less effective than newer OMMs (semaglutide, tirzepatide) and have limited long-term data.

Endoscopic procedures (IGB, AT, POSE, ESG) offer moderate weight loss (3.8-12.8% TBWL) in the short term but are generally less effective than newer medications (semaglutide, tirzepatide) and lack long-term efficacy data. They may be considered for patients who are not candidates for surgery or high-dose medications, but they are not the most effective option for significant, sustained weight loss.

ModerateRefutesMEDIUM confidence
EBP, except ESG, was less effective than newer OMMs. Long- term data were lacking for most OMM and all EBP.
Maurizio De Luca et al. · Obesity · 2026

Why this rating

Based on 21 RCTs (n=2934), with limited long-term follow-up data available.

Source

Efficacy and Safety of Pharmacological, Endoscopic, and Surgical Treatments for Obesity: A <scp>GRADE</scp> ‐Based Network Meta‐Analysis

Maurizio De Luca et al. · Obesity · 2026

DOI 10.1002/oby.70083

Meta-analysis · 139 studiesCited 1×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →